Two cases of toxic hepatitis developing in patients receiving high-dose etoposide (VP-16-213) for refractory germinal neoplasms are described. Each patient received a total cumulative dose of at least 6,800 mg/m2. Liver function abnormalities, including hyperbilirubinemia, elevated transminases, and elevated alkaline phosphatase, became clinically apparent approximately 3 weeks following the last dose of VP-16-213. These abnormalities resolved spontaneously without sequelae over 12 weeks. High-dose VP-16-213 may be associated with hepatic injury.
|Original language||English (US)|
|Number of pages||2|
|Journal||Cancer Treatment Reports|
|State||Published - Dec 1 1983|
ASJC Scopus subject areas
- Cancer Research